MCL Literature Feed

This case of cardiac MCL with a mobile tumor highlights the risk of fatal pulmonary embolism post-chemotherapy, suggesting a potential role for pre-treatment surgical intervention in this rare presentation.

SOX11-negative, CCND1-rearranged large B-cell lymphomas can arise via a DLBCL-like mechanism (aberrant CSR/SHM), distinguishing them genetically from classic MCL and highlighting a potential diagnostic challenge.

This case of atypical plasma cell leukemia, initially misdiagnosed as blastoid mantle cell lymphoma, highlights the critical diagnostic challenge of distinguishing between aggressive, morphologically similar hematologic malignancies.

Preclinical data shows the novel CTPS1 inhibitor STP-B has single-agent activity in high-risk MCL (blastoid, TP53-mutated) and synergizes with venetoclax by downregulating MCL1, offering a new combination strategy.

This study identifies a rare CD5/SOX11 double-negative pleomorphic MCL, showing CCND1 rearrangement is the key feature to differentiate it from cyclin D1-positive DLBCL, ensuring correct diagnosis.

This review explains MCL's clinical heterogeneity through distinct molecular subtypes and genomic alterations like TP53, which serve as key prognostic biomarkers and guide development of novel therapies.

This large Chinese retrospective study of blastoid/pleomorphic MCL links progression of disease within 12 months (POD12) to a distinct mutation profile (TP53, SMARCA4) and poor prognosis.

This review synthesizes current knowledge on MCL genetic markers, advocating for a personalized medicine approach that integrates molecular profiles like TP53 to improve risk stratification and guide therapy.

Transformed MCL with triple-hit genetics (MYC/BCL2/BCL6 rearrangements) can be resistant to BTK inhibitors, identifying a novel genomic mechanism of treatment failure in this aggressive setting.

Gene expression profiling identifies two distinct molecular MCL subtypes, C1 and C2, with C2 showing high proliferation and poor prognosis, providing a powerful new biomarker for risk stratification.

This B-ALL study reveals MALT1 inhibitors downregulate MYC, providing a novel mechanism and strong rationale for testing this strategy in aggressive, MYC-driven mantle cell lymphoma.

MYC overexpression is a critical biomarker defining high-risk mantle cell lymphoma, helping to stratify patients with poor prognosis and potentially guiding novel therapeutic approaches for this aggressive disease.

This review summarizes fundamental MCL characteristics, including the t(11;14) translocation and key high-risk features (high Ki67, blastoid variant, TP53 mutation) essential for patient risk stratification.

Real-world UK data show first-line ibrutinib is effective and tolerable for older MCL patients, but high-risk subgroups (TP53-mutated, blastoid) have significantly inferior survival, highlighting an unmet need.

Large B-cell lymphoma with IRF4 rearrangement can mimic blastoid MCL by presenting in older adults and expressing CD5, but negativity for Cyclin D1 and SOX11 is crucial for differential diagnosis.

Palliative radiotherapy provided profound tumor reduction for an elderly patient with blastoid MCL presenting as a rare oropharyngeal mass, demonstrating a personalized, less-intensive frontline treatment option.

SOX11 expression in cyclin D1-negative large B-cell neoplasms defines them as a variant of blastoid MCL, not DLBCL, solidifying SOX11 as a crucial diagnostic marker for aggressive MCL.

This pathology workshop report clarifies the differential diagnosis of aggressive B-cell lymphomas, including pleomorphic MCL, by applying updated WHO-HAEM5 and ICC 2022 classifications for improved diagnostic accuracy.

Combining the MCL35 gene signature with s-MIPI and blastoid cytology powerfully risk-stratifies older, frontline MCL patients receiving bendamustine-rituximab, identifying a dismal prognosis subgroup.

This dual-center retrospective analysis of 20 patients with blastoid MCL characterizes its clinical features and prognosis, adding to the limited evidence base for this aggressive subtype.

This case of blastoid MCL with aberrant CD10 expression highlights a rare immunophenotype, creating a diagnostic pitfall that can mimic other aggressive B-cell lymphomas.

This case report describes a rare transformation of CD5-negative MCL into an EBV-positive pleomorphic variant, highlighting a potential role for EBV in aggressive disease progression and diagnosis.

This single-center retrospective study characterizes the aggressive clinical and pathological features of blastoid MCL, underscoring its diagnostic challenges and the need for novel therapeutic approaches for this high-risk subtype.

This review summarizes the evolving Japanese MCL treatment landscape, highlighting novel therapies like BTKi, BCL2i, and CAR-T to address resistance in high-risk subsets like TP53-mutated and blastoid.

This case of classical MCL rapidly transforming to a blastoid variant with CNS involvement highlights the poor prognosis and failure of BTKi and chemotherapy in this aggressive setting.